Used Services and Cookies

Our website uses cookies to enhance your user experience. Some cookies are essential for the operation and management of the site, while others are used for anonymous statistics or personalized content. Please note that limiting cookie use may impair certain functions of the website.

More information: Imprint, Data protection

Essential cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website or, for example, saving your cookie settings. The website cannot function properly without these cookies. This category cannot be deactivated.
  • Name:
    ukie_a_cookie_consent_manager
  • Domain:
    blomstein.com
  • Purpose:
    Stores the cookie preferences of website visitors.
  • Name:
    blomstein_session
  • Domain:
    blomstein.com
  • Purpose:
    The session cookie is essential for the basic functioning of the website. It allows users to navigate through the site and use its basic features.
  • Name:
    XSRF-TOKEN
  • Domain:
    blomstein.com
  • Purpose:
    This cookie serves security purposes and aids in preventing Cross-Site Request Forgery (CSRF) attacks. It is a technical necessity.
These cookies collect information about how you use a website, e.g. which pages you have visited and which links you have clicked on.
  • Name:
    _ga
  • Domain:
    blomstein.com
  • Purpose:
    The Google Analytics cookie _ga is used to distinguish users by assigning a unique identification number to each visitor. This number is sent to Google Analytics each time a page is accessed in order to collect user, session and campaign data and to statistically evaluate the use of the website. The cookie helps website operators to understand how visitors interact with the website by collecting information anonymously and generating reports.
  • Name:
    _ga_*
  • Domain:
    blomstein.com
  • Purpose:
    The _ga_[container_id] cookie, specific to Google Analytics 4 (GA4), is used to distinguish website visitors by assigning a unique ID for each session and each user. It enables the collection and analysis of data on user behavior on the website in anonymized form. This includes tracking page views, interactions and the path users take on the website to give website operators deeper insights into the use of their site and improve the user experience.
  • Name:
    _gid
  • Domain:
    blomstein.com
  • Purpose:
    The _gid cookie is a cookie set by Google Analytics that is used to distinguish users. It assigns a unique identification number to each visitor to the website, which is sent to Google Analytics each time the page is accessed. This makes it possible to track and analyze user behavior on the website over a period of 24 hours.
  • Name:
    _gat_gtag_UA_77241503_1
  • Domain:
    blomstein.com
  • Purpose:
    The _gat_gtag_UA_77241503_1 cookie is part of Google Analytics and Google Tag Manager and is used to throttle the request rate, i.e. it limits data collection on high traffic websites. This cookie is linked to a specific Google Analytics property ID (in this case UA-77241503-1), which means that it is used for performance monitoring and control of data collection for that specific website property.

(Even) More control when acquiring companies in the healthcare sector (15th amendment of the Foreign Trade and Payments Ordinance – AWV)

29.04.2020

With the 15th amendment of the Foreign Trade and Payments Ordinance (AWV), the Federal Ministry for Economic Affairs and Energy will soon extend its control over acquisitions of German companies by EU foreign companies. The amendment is perceived as the Federal Government’s direct reaction to the COVID-19 crisis, due to its concern in large part to protect the healthcare sector. The case of the Tübingen-based company CureVac, involving a US purchaser and raising the question of the right of prohibition, may have also contributed to this development. The 16th amendment to the AWV is expected to comprehensively expand and adapt investment control in foreign trade law. It is aimed at uniformly implementing Regulation (EU) 2019/452 (*_EU Screening Regulation*_), which came into force in April 2019, and the amendment to the Foreign Trade and Payments Act (AWG) adopted already by the Cabinet on 8th April 2020. Since the latter remains under discussion in the committees of the Bundestag, the Federal Ministry for Economic Affairs and Energy has brought forward what it considers to be particularly urgent adjustments.

Changes to the healthcare sector due to the new AWV

The key change is the addition of five examples of entrepreneurial activity in the healthcare sector that, in the context of a cross-sectoral review pursuant to Section 55 para. 1 sentence 2 AWV, could pose a threat to public safety and order. This concerns domestic companies that develop, manufacture or distribute

  • personal protective equipment (No. 8),

  • essential medicines (No. 9),

  • medical products used against life-threatening and highly contagious infectious diseases (No. 10) or

  • in vitro diagnostics (No. 11).

Affected companies are broadly defined; production facilities and technologies applied for the development and manufacture of the above-mentioned products are also treated in the same way as companies (Section 55 para. 1 sentence 3 AWV). For a risk to be identified, it is sufficient if only a discrete part or essential operating material of the company are part of the implicated contract (Section 55 para. 1a AWV).

Furthermore, the Federal Ministry for Economic Affairs issued guidelines for the investor-related assessment of a risk. In particular, pursuant to Section 55 para. 1b AWV, it takes into account

  • whether the government of a third country is involved in the acquisition,

  • whether the acquirer has already been involved in activities which have had a negative impact on public safety and order, and

  • whether there is a significant risk of certain criminal or administrative offences.

Current practice already takes State influence into consideration, especially in the case of investments from the People’s Republic of China. The new regulation leaves the practical problems unaddressed. While State influence may indicate a threat, there must be provision for the company to prove otherwise, taking into account the particularities of each case.

Additional extension to companies in the communication infrastructure and the extraction or processing of raw materials

In addition to the healthcare sector and in the context of implementing the EU Screening Regulation, the Federal Ministry for Economic Affairs will also place two other systemically relevant areas under its control. Firstly, it targets companies that provide necessary services to ensure fault-free and functioning state communication infrastructure (Section 55 para. 1 sentence 2 no. 7 AWV). Secondly, it affects companies that extract or process raw materials or ores (Section 55 para. 1 sentence 2 no. 12 AWV).

Stricter control when acquiring companies under the AWG

For newly listed companies, the extension of the catalogue means that, as of the entry into force of the new AWV, the acquisition of shares in at least 10 percent of these companies by a non-EU acquirer is now subject to notification and comprehensive examination by the Federal Ministry for Economic Affairs. When the amendment to the AWG enters into force – expected in a matter of weeks – certain transactions may be prohibited and sanctioned. In addition, the transaction will be provisionally invalid under civil law until it is approved.

Conclusion

The 15th amendment of the AWV appears to be a direct response to the COVID-19 crisis. It nevertheless coheres with the Industrial Strategy 2030 announced by Federal Minister of Economics Peter Altmaier in November 2019, which envisages further tightening of investment controls. It remains to be seen whether such tightened controls will make Germany (even) less attractive as a liberal investment location (see also our briefing of 9th April 2020). In practice, these changes mean that investment control under foreign trade law in the context of transactions will continue to grow in importance. The duration of proceedings is expected to increase, which must be taken into account in the transaction schedule.

BLOMSTEIN will monitor further developments. If you have any questions about the potential impact of these changes to foreign trade law on your company or your industry, Roland M. Stein and Leonard von Rummel will be happy to answer them.

back to overview